AMENDMENTS TO THE CLAIMS

- 1 39. (Canceled)
- 40. (Currently Amended) A composition, comprising milk derived from a transgenic mammal and a recombinant transgenic polypeptide <u>having a concentration of at least 0.5 mg/ml</u> wherein said polypeptide comprises a completely γ-carboxylated Gla domain and a first amino acid sequence, wherein said first sequence is identical to a human prothrombin amino acid sequence.
- 41. (Canceled)
- 42. (Previously Presented) The composition of Claim 40, wherein polypeptide comprises a post-translational modification selected from the group consisting of glycosylation and proteolytic processing.
- 43. (Canceled)
- 44. (Previously Presented) The composition of Claim 40, wherein said polypeptide further comprises a second amino acid sequence, wherein said second sequence is identical to a mammalian thrombin amino acid sequence.
- 45. (Canceled)
- 46. (Previously Presented) The composition of Claim 44, wherein said mammalian thrombin comprises human thrombin.
- 47-55. (Canceled)
- 56. (Previously Presented) The composition of Claim 42, wherein said proteolytic processing comprises enzymatic cleavage selected from the group consisting of Factor Xa, Factor Va, venom protease, thrombin, and combinations thereof.

Attorney-Docket No.: AIB-08252

57. (Previously Presented) The composition of Claim 42, wherein said proteolytic processing comprises chemical activation selected from the group consisting of sodium citrate, protamine sulfate, polylysine, and combinations thereof.

- 58. (Previously Presented) The composition of Claim 42, wherein said proteolytic processing comprises, in combination, Factor Xa, Factor Va, calcium, and phospholipids.
- 59-60. (Canceled)
- 61. (Previously Presented) The composition of Claim 40, wherein said first amino acid sequence is 100% identical to said human prothrombin amino acid sequence, wherein upon activation said prothrombin sequence is capable of being converted into thrombin.